Herein, we describe the development of a population pharmacokinetics (PopPK) model characterizing SAF-189s plasma PKs based on data from its phase I/II study in Chinese patients with ALK+/ROS1+ NSCLC as well as a food effects study in healthy Chinese volunteers. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.